News

In the U.S., the total cost of Parkinson’s disease — including direct medical costs and lost productivity from patients and caregivers — was more than $82 billion in 2024, according to a new report from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The findings build on…

Scientists have demonstrated that it is possible to collect individualized data on how connections among brain circuits change for people with Parkinson’s disease who are undergoing deep brain stimulation (DBS) as a treatment for their symptoms. These findings lay the groundwork for more individualized approaches for DBS, and…

Fecal transplant — a procedure in which stool from healthy donors is transferred into a patient’s gut to restore a more normal bacterial balance — safely eased motor symptoms and constipation in adults with early, untreated Parkinson’s disease, according to a study. These patients also reported improvements in quality…

The Parkinson’s Foundation‘s largest annual fundraiser — Moving Day, A Walk for Parkinson’s — is marking its 15th anniversary, and the U.S.-based nonprofit has announced dates for a series of walks across the nation that aim to generate funding that will advance research and support care for people with…

April will be an activity-filled month for people living with Parkinson’s disease — and for doctors, researchers, and advocates — as the world recognizes Parkinson’s Awareness Month and World Parkinson’s Day on April 11. “For most people and their families, a Parkinson’s diagnosis is difficult…

Scientists in Denmark are embarking on a three-year project aiming to develop a Parkinson’s disease treatment that blocks the spread of toxic alpha-synuclein protein in the brain. “This breakthrough project positions Denmark at the forefront of Parkinson’s disease research, with a…

The first few participants in a clinical trial have reported notable easing of motor symptoms following treatment with Oryon Cell Therapies’  Parkinson’s disease therapy, according to data released by the company. Data also indicate that Oryon’s therapy, which aims to replace lost brain cells with new nerve cells engineered…

Serina Therapeutics has entered into definitive agreements for a private placement that could provide up to $30 million to support the advancement of its clinical trial evaluating SER-252 (POZ-apomorphine) as a treatment for people with advanced Parkinson’s disease. The global Phase 1b trial (NCT07422675) is evaluating the…

Treatment with pirepemat, an oral medication in the pipeline at Irlab Therapeutics AB, may help reduce the risk of falls in people with Parkinson’s disease when reaching its optimal blood concentration, according to newly shared data from a clinical trial in Europe. “Topline results showed a markedly reduced…

Scientists have developed an experimental gene therapy with the potential to treat early-onset Parkinson’s disease associated with PRKN gene mutations, according to a new preclinical study. Delivery of the gene therapy carrying a functional version of the PRKN gene into the brains of two mouse…